If you get a partnership in DKD, why bother waisting money on a FSGS study? How is fsgs attractive if youve priced the drug for DKD?
Ann: Dimerix Plans for Next Study in Diabetic Kidney Disease, page-58
-
- There are more pages in this discussion • 112 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $225.9M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 40.5¢ | 40.0¢ | $2.813K | 6.996K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4652 | 40.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 108685 | 6 |
View Market Depth
| Last trade - 10.22am 11/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |